Motus GI to Present at the JMP Securities Life Sciences Conference
– Presentation with live audio webcast on Wednesday, June 19th
at 10:30 AM ET –
FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Motus
GI Holdings, Inc., (NASDAQ:MOTS) (“Motus GI” or the “Company”), a
medical technology company dedicated to improving clinical outcomes and
enhancing the cost-efficiency of colonoscopy, announced today that Tim
Moran, Chief Executive Officer, will present a company overview and
update at the JMP Securities Life Sciences Conference on Wednesday, June
19, 2019 at 10:30 AM ET in New York, NY.
A live audio webcast
of the presentation will be accessible on the Events
page of the Investors
section on the Company’s website at www.motusgi.com.
The webcast replay will be available approximately two hours after the
presentation ends and will be accessible for 90 days.
About Motus GI and the Pure-Vu® System
Motus GI Holdings, Inc. is a medical technology company, with
subsidiaries in the U.S. and Israel, dedicated to improving clinical
outcomes and enhancing the cost-efficiency of colonoscopy. The Company’s
flagship product is the Pure-Vu® System, a U.S. FDA cleared
medical device indicated to help facilitate the cleaning of a poorly
prepared colon during the colonoscopy procedure. The device integrates
with standard and slim colonoscopes to enable safe and rapid cleansing
during the procedure while preserving established procedural workflow
and techniques. The first generation of the Pure-Vu® System
has received CE mark approval in Europe. The Pure-Vu® System
is currently being introduced on a pilot basis in the U.S. market, and
the Company is planning to initiate a commercial launch focused on the
U.S. hospital market in 2019. Challenges with bowel preparation for
inpatient colonoscopy represent a significant area of unmet need that
directly affects clinical outcomes and increases the cost of care in a
market segment that comprises approximately 1.5 million annual
procedures in the U.S. and approximately 4 million annual procedures
worldwide. Motus GI believes the Pure-Vu® System may improve
outcomes and lower costs for hospitals by reducing the time to
successful colonoscopy, minimizing delayed and incomplete procedures,
and improving the quality of an exam. In clinical studies to date, the
Pure-Vu® System significantly increased the number of
patients with an adequate cleansing level, according to the Boston Bowel
Preparation Scale Score, a validated assessment instrument.
For more information, visit www.motusgi.com
and connect with the Company on Twitter,
LinkedIn
and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements.
Forward-looking statements are based on the Company’s current
expectations and assumptions. The Private Securities Litigation Reform
Act of 1995 provides a safe-harbor for forward-looking statements. These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,” “intend,” “plan,”
“believe,” “estimate,” “potential,” “predict,” “project,” “should,”
“would” and similar expressions and the negatives of those terms,
including without limitation, risks inherent in the development and
commercialization of potential products, uncertainty in the timing and
results of clinical trials or regulatory approvals, maintenance of
intellectual property rights or other risks discussed in the Company’s
Form 10-K filed on March 26, 2019, and its other filings with the
Securities and Exchange Commission. Prospective investors are cautioned
not to place undue reliance on such forward-looking statements, which
speak only as of the date hereof. The Company undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise.
Contacts
Investors:
Jenene Thomas
Jenene
Thomas Communications, LLC
(833) 475-8247
mots@jtcir.com
Media:
Erich A. Sandoval
Lazar
Partners
(917) 497-2867
esandoval@lazarpartners.com
